

AMENDED IN ASSEMBLY AUGUST 7, 2006

AMENDED IN ASSEMBLY JUNE 20, 2006

AMENDED IN SENATE MAY 26, 2006

AMENDED IN SENATE APRIL 26, 2006

AMENDED IN SENATE APRIL 6, 2006

SENATE BILL

No. 1260

Introduced by Senators Ortiz and Runner

February 9, 2006

An act to amend Sections 125118, 125119, 125119.3, ~~and 125119.5~~ *125119.5, and 125300* of, and to add Chapter 2 (commencing with Section 125330) to Part 5.5 of Division 106 of, the Health and Safety Code, relating to reproductive health.

LEGISLATIVE COUNSEL'S DIGEST

SB 1260, as amended, Ortiz. Reproductive health and research.

The California Stem Cell Research and Cures Act, an initiative measure approved by the voters at the November 2, 2004, general election (Proposition 71), establishes the California Institute for Regenerative Medicine, the purpose of which is, among other things, to make grants and loans for stem cell research, for research facilities, and for other vital research opportunities to realize therapies, protocols, and medical procedures that will result in, the cure for, or substantial mitigation of, diseases and injuries. Existing law establishes the Independent Citizen's Oversight Committee (ICOC), composed of appointed members, that is required to perform various functions and duties with regard to the operation of the institute,

including, but not limited to, establishing standards applicable to research funded by the institute.

Existing law prohibits amendment of Proposition 71 by the Legislature unless the amendment is approved by the voters, or the amendment is accomplished by a bill introduced after the first 2 full calendar years and approved by a vote of 70% of both houses.

Existing law, which is not applicable to research funded under Proposition 71, and which would be repealed on January 1, 2007, requires the State Department of Health Services to, among other things, develop guidelines for research involving the derivation or use of embryonic stem cells, and to report annually to the Legislature.

This bill would delete the repeal date of those provisions, thus indefinitely extending their duration. The bill would also revise the department's reporting duties, by requiring biennial rather than annual reports to the Legislature.

Existing law requires research projects involving the derivation or use of human embryonic stem cells to be reviewed and approved by an institutional review board established in accordance with federal regulations.

This bill would *revise a related declaration of state policy, would* require these research projects to instead be reviewed and approved by a stem cell research oversight committee established substantially in accordance with specified guidelines, *and would make these provisions applicable also to research projects involving human adult stem cells.*

Existing law applicable to fertility treatment requires that a physician and surgeon provide a patient with prescribed information and obtain the patient's informed consent prior to providing the fertility treatment.

This bill, with certain exceptions, would require a physician and surgeon, prior to conducting assisted oocyte production, as defined, or other method of ovarian retrieval for purposes of retrieving eggs for research or for developing medical therapies, to provide the subject with a standardized written summary of health and consumer issues and to obtain the subject's written and oral informed consent for the procedure.

Existing law prohibits a person from knowingly, for valuable consideration, purchasing or selling embryonic or cadaveric fetal tissue for research purposes.

This bill would prohibit human oocytes or embryos from being acquired, sold, offered for sale, received, or otherwise transferred for valuable consideration for medical research or development of medical therapies, and would prohibit payment in excess of the amount of reimbursement of expenses to be made to any research subject to encourage her to produce human oocytes for the purposes of medical research.

The bill would declare that it is not to be construed to amend Proposition 71, ~~and would encourage the ICOC to take prescribed actions, including, but not limited to, reviewing studies concerning the health risks and benefits of ovarian stimulation drugs, and undertaking further research.~~

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: no.

The people of the State of California do enact as follows:

- 1 SECTION 1. The Legislature finds and declares all of the
- 2 following:
- 3 (a) The purpose of this act is to create protections for research
- 4 subjects and it should not be construed to affect any other form
- 5 of medical care.
- 6 (b) Scientific research can be most effectively achieved by
- 7 establishing protocols to protect, respect, and promote human
- 8 health, safety, dignity, autonomy, and rights in conducting
- 9 research.
- 10 (c) This act seeks to support the requirements already in
- 11 current law upholding the principle of voluntary and informed
- 12 consent and to tailor them to this new area of pioneering research
- 13 that utilizes human oocytes.
- 14 (d) The potential for exploitation of the reproductive
- 15 capabilities of women for commercial gain raises health and
- 16 ethical concerns that justify the prohibition of payment for
- 17 human oocytes.
- 18 SEC. 2. Section 125118 of the Health and Safety Code is
- 19 amended to read:
- 20 125118. (a) The Maternal, Child, and Adolescent Health
- 21 Branch of the State Department of Health Services shall develop
- 22 guidelines for research involving the derivation or use of human
- 23 embryonic stem cells in California.

(b) In developing the guidelines specified in subdivision (a), the branch may consider other applicable guidelines developed or in use in the United States and in other countries, including, but not limited to, the Guidelines for Research Using Human Pluripotent Stem Cells developed by the National Institutes of Health and published in August 2000, and corrected in November 2000, and the Guidelines for Human Embryonic Stem Cell Research issued by the National Research Council and Institute of Medicine of the National Academies in 2005.

SEC. 3. Section 125119 of the Health and Safety Code is amended to read:

125119. (a) (1) All research projects involving the derivation or use of human embryonic stem cells shall be reviewed and approved by a stem cell research oversight committee prior to being undertaken. Any stem cell research oversight committee shall, in its review of human embryonic stem cell research projects, consider and apply the guidelines developed by the department pursuant to Section 125118. A stem cell research oversight committee may require modifications to the plan or design of a proposed human embryonic stem cell research project as a condition of approving the research project.

(2) A stem cell research oversight committee for purposes of this article shall be established substantially in accordance with Guidelines for Human Embryonic Stem Cell Research issued by the National Research Council and the Institute of Medicine of the National Academies in 2005.

(b) Not less than once per year, a stem cell research oversight committee shall conduct continuing review of human embryonic stem cell research projects reviewed and approved under this section in order to ensure that the research continues to meet the standards for stem cell research oversight committee approval. Pursuant to its review in accordance with this subdivision, a stem cell research oversight committee may revoke its prior approval of research under this section and require modifications to the plan or design of a continuing research project before permitting the research to continue.

(c) A stem cell research oversight committee may provide scientific and ethical review of research consistent with this article.

1 SEC. 4. Section 125119.3 of the Health and Safety Code is
2 amended to read:

3 125119.3. (a) Each stem cell research oversight committee
4 that has reviewed human embryonic stem cell research pursuant
5 to Section 125119 shall report to the department, annually, on the
6 number of human embryonic stem cell research projects that the
7 stem cell research oversight committee has reviewed, and the
8 status and disposition of each of those projects, including the
9 information collected pursuant to Section 125342.

10 (b) Each stem cell research oversight committee shall also
11 report to the department regarding unanticipated problems,
12 unforeseen issues, or serious continuing investigator
13 noncompliance with the requirements or determinations of the
14 stem cell research oversight committee with respect to the review
15 of human embryonic stem cell research projects, and the actions
16 taken by the stem cell research oversight committee to respond to
17 these situations.

18 SEC. 5. Section 125119.5 of the Health and Safety Code is
19 amended to read:

20 125119.5. (a) The department shall at least annually review
21 reports from stem cell research oversight committees, and may
22 revise the guidelines developed pursuant to Section 125118, as it
23 deems necessary.

24 (b) The department shall report biennially to the Legislature
25 on human embryonic stem cell research activity. These biennial
26 reports shall be compiled from the reports from stem cell
27 research oversight committees.

28 SEC. 6. *Section 125300 of the Health and Safety Code is*
29 *amended to read:*

30 ~~125300. The policy of the State of California shall be as~~
31 ~~follows:~~

32 ~~(a) That research involving the derivation and use of human~~
33 ~~embryonic stem cells, human embryonic germ cells, and human~~
34 ~~adult stem cells from any source, including somatic cell nuclear~~
35 ~~transplantation, shall be permitted and that full consideration of~~
36 ~~the ethical and medical implications of this research be given.~~

37 ~~(b) That~~

38 *125300. The policy of the State of California shall be that*
39 *research involving the derivation and use of human embryonic*
40 *stem cells, human embryonic germ cells, and human adult stem*

1 cells, including somatic cell nuclear transplantation, shall be
2 reviewed by an approved institutional review board.

3 ~~SEC. 6.~~

4 *SEC. 7.* Chapter 2 (commencing with Section 125330) is
5 added to Part 5.5 of Division 106 of the Health and Safety Code,
6 to read:

7
8 CHAPTER 2. PROCURING OF OOCYTES FOR RESEARCH
9

10 125330. The following definitions shall apply to this chapter:

11 (a) “Assisted oocyte production” or “AOP” means surgical
12 extraction of oocytes following pharmaceutically induced
13 manipulation of oocyte production through the use of ovarian
14 stimulation.

15 (b) “Oocyte” means a female egg or egg cell of a human
16 female.

17 (c) “Subject” means any person undergoing AOP or any
18 alternative method of ovarian retrieval for research or for the
19 development of medical therapies, including those who would
20 not meet the definition of “subject” under 45 C.F.R. 46.102.

21 (d) “Alternate method of oocyte retrieval” means a method of
22 oocyte retrieval that does not involve the pharmaceutically
23 induced manipulation of oocyte production.

24 (e) “Institutional review board” means a body established in
25 accordance with federal regulations, including Part 46
26 (commencing with Section 46.101) of Subchapter A of Subtitle
27 A of Title 45 of the Code of Federal Regulations.

28 125335. (a) Prior to conducting AOP or any alternative
29 method of ovarian retrieval on a subject for the purpose of
30 procuring oocytes for research or the development of medical
31 therapies, a physician and surgeon shall provide to the subject a
32 standardized medically accurate written summary of health and
33 consumer issues associated with AOP and any alternative
34 methods of oocyte retrieval. The failure to provide to a subject
35 this standardized medically accurate written summary constitutes
36 unprofessional conduct within the meaning of Chapter 5
37 (commencing with Section 2000) of Division 2 of the Business
38 and Professions Code.

39 (b) The summary shall include, but not be limited to,
40 medically accurate disclosures concerning the potential risks of

1 AOP or any alternative method of oocyte retrieval, including the
2 risks associated with the surgical procedure and with using the
3 drugs, medications, and hormones prescribed for ovarian
4 stimulation during the AOP process or any alternative method of
5 oocyte retrieval.

6 (c) For purposes of subdivision (a), “written summary of
7 health and consumer issues” means the guide published and
8 updated by the American Society for Reproductive Medicine
9 entitled, “Assisted Reproductive Technology: A Guide for
10 Patients” or an alternative written medically accurate document
11 prepared by a recognized authority on oocyte retrieval for
12 medical research that also meets the criteria included in this
13 section. This alternative document may be one that has been
14 approved and recommended by the State Department of Health
15 Services pursuant to Section 125118 and shall include all of the
16 following:

17 (1) The document shall adhere to simplified reading standards,
18 including, but not limited to, those generally accepted and
19 required for government publications. The document shall be
20 written in layperson’s language and shall be made available in
21 languages spoken by subjects in the study if their proficiency is
22 largely in a language other than English. All information in the
23 document shall be conveyed to the subject orally in easy to
24 understand and nontechnical terms.

25 (2) The document shall include additional resources for, or list
26 additional sources of, medical information on health and safety
27 issues surrounding oocyte retrieval.

28 125340. (a) Prior to providing AOP or any alternative
29 method of ovarian retrieval to a subject for the purposes of
30 medical research or development of medical therapies, a
31 physician and surgeon shall obtain written and oral informed
32 consent for the procedure from the subject. Informed consent for
33 the purposes of this chapter shall comply with the informed
34 consent requirements of the Protection of Human Subjects in
35 Medical Experimentation Act (Chapter 1.3 (commencing with
36 Section 24170) of Division 20).

37 (b) The failure to obtain written informed consent from the
38 subject constitutes unprofessional conduct within the meaning of
39 Chapter 5 (commencing with Section 2000) of Division 2 of the
40 Business and Professions Code. Nothing in this section shall be

1 construed to relieve the physician and surgeon from other
2 existing duties under the law, including, but not limited to, the
3 duty to obtain a subject's informed consent after fully explaining
4 the proposed procedure. The requirement that a physician and
5 surgeon provide the standardized written summary pursuant to
6 Section 125335 is in addition to, and does not supplant, other
7 existing legal requirements regarding informed consent,
8 including, but not limited to, compliance with the Protection of
9 Human Subjects in Medical Experimentation Act (Chapter 1.3
10 (commencing with Section 24170) of Division 20.

11 (c) This chapter shall not affect the suitability or availability of
12 oocytes procured for research before January 1, 2007, if the
13 oocytes were donated pursuant to protocols or standards that are
14 generally recognized and accepted by national or international
15 scientific bodies.

16 (d) Any written document required pursuant to this section
17 shall adhere to simplified reading standards, including, but not
18 limited to, those generally accepted and required for government
19 publications, and in layperson's language. The document shall be
20 made available in languages spoken by subjects in the study if
21 their proficiency is largely in a language other than English. All
22 information in the written informed consent document shall also
23 be conveyed to the subject orally in easy to understand and
24 nontechnical terms.

25 125341. An institutional review board (IRB) that reviews and
26 approves medical and scientific research shall require all of the
27 following of any research program or project that comes under its
28 review that involves AOP or any alternative method of oocyte
29 retrieval:

30 (a) That it include a written summary as required under
31 Section 125335 that would include information on health risks
32 and potential adverse consequences of the procedure and
33 describe the manner in which the subject will receive and review
34 this written summary.

35 (b) That it obtain informed consent in compliance with the
36 Protection of Human Subjects in Medical Experimentation Act
37 (Chapter 1.3 (commencing with Section 24170) of Division 20),
38 including informed consent for information obtained pursuant to
39 Section 125342.

1 (c) That it provide the subject with an objective and accurate
2 statement about the existing state of the research for which the
3 subject is providing oocytes.

4 (d) That it perform psychological and physical screening, in
5 accordance with the appropriate standard of care, for all subjects
6 prior to the oocyte retrieval procedure.

7 (e) That it ensure that after conducting AOP or any alternative
8 method of oocyte retrieval on a subject, the subject be given a
9 postprocedure medical examination at a time within the standard
10 of care to determine if the subject has experienced an adverse
11 health effect that is a result of the procedure. The subject shall be
12 informed that she has the right to a second opinion if she has any
13 medical concerns.

14 (f) That it ensure that the subject has access to and coverage
15 for medically appropriate medical care that is required as a direct
16 result of the *research* procedure. The research program or project
17 shall ensure that payment or coverage of resulting medical
18 expenses be provided at no cost to the subject and that a
19 summary of the arrangements the procuring entity has made for
20 coverage or payment for medical care related to AOP or any
21 alternative method of oocyte retrieval is provided to the subject
22 prior to the procedure.

23 (g) That it provide a summary informing the subject that
24 oocytes may not be sold or transferred for valuable consideration
25 except as set forth in Section 125350.

26 (h) That it provide disclosure if the physician and surgeon and
27 his or her immediate family members have any professional
28 interest in the outcome of the research or of the oocyte retrieval
29 procedure and, if so, that it provide disclosure that he or she
30 carries the interest of both the subject and the success of the
31 research.

32 125342. (a) A research program or project that involves
33 AOP or any alternative method of oocyte retrieval ~~for research~~
34 ~~purposes~~ shall ensure that a written record is established and
35 maintained to include, but not be limited to, all of the following
36 components:

37 (1) The demographics of subjects, including, but not limited
38 to, their age, race, primary language, ethnicity, income bracket,
39 education level, and the first three digits of the ZIP Code of
40 current residence.

1 (2) Information of every oocyte that has been donated or used.
2 This record should be sufficient to determine the provenance and
3 disposition of those materials.

4 (3) A record of all adverse health outcomes, including, but not
5 limited to, incidences and degrees of severity, resulting from the
6 AOP or any alternative method of oocyte retrieval.

7 (b) The information included in the written record pursuant to
8 subdivision (a) shall not disclose personally identifiable
9 information about subjects, and shall be confidential and is
10 deemed protected by subject privacy provisions of law. This
11 information shall be reported to the Maternal, Child, and
12 Adolescent Health Branch of the State Department of Health
13 Services, which shall aggregate the data and make it publicly
14 available in a manner that does not reveal personally identifiable
15 information about the subjects.

16 125343. Any employee who works in the unit conducting
17 stem cell research using human oocytes, persons who report to,
18 or are supervised by, the principal investigator or key personnel
19 of the project, or both, along with the principal investigator and
20 the key personnel of the project, and the immediate family
21 members of any of the above persons are prohibited from being a
22 subject in the research.

23 125344. The physician and surgeon performing the AOP or
24 any alternative method of oocyte retrieval shall not have a
25 financial interest in the outcome of the research.

26 125345. Pursuant to guidelines adopted by the Research
27 Council and Institute of Medicine of the National Academies,
28 researchers shall offer subjects an opportunity to document their
29 preferences regarding future uses of their donated materials. The
30 consent process shall fully explore whether ~~donors~~ *subjects* have
31 objections to any specific forms of research to ensure that their
32 wishes are honored.

33 125346. Any procedures for procuring oocytes in this state
34 for research or the development of medical therapies shall meet
35 all of the standards for subjects included in this chapter. All
36 oocytes procured outside of this state for research taking place in
37 this state shall meet these same standards. All egg extractions for
38 research shall be approved by an institutional review board
39 pursuant to Section 125341.

1 125350. No human oocyte or embryo shall be acquired, sold,
2 offered for sale, received, or otherwise transferred for valuable
3 consideration for the purposes of medical research or
4 development of medical therapies. For purposes of this section,
5 “valuable consideration” does not include reasonable payment
6 for the removal, processing, disposal, preservation, quality
7 control, and storage of oocytes or embryos.

8 125355. No payment in excess of the amount of
9 reimbursement of direct expenses incurred as a result of the
10 procedure shall be made to any research subject to encourage her
11 to produce human oocytes for the purposes of medical research.

12 ~~SEC. 7. (a) This~~

13 *SEC. 8. This* act shall not be construed to amend Proposition
14 71, approved by the voters at the November 2, 2004, general
15 election.

16 ~~(b) The Independent Citizen’s Oversight Committee (ICOC)~~
17 ~~established pursuant to Section 125290.15 of the Health and~~
18 ~~Safety Code is encouraged to review existing studies concerning~~
19 ~~the health risks and benefits of ovarian stimulation drugs used for~~
20 ~~assisted oocyte production, identify gaps in existing knowledge~~
21 ~~concerning health risks and benefits, and undertake further~~
22 ~~research as the ICOC deems necessary to characterize the risks~~
23 ~~and benefits of those drugs.~~